March 12, 2018—A federal appeals court will hear oral arguments on May 4 from hospital groups and health systems that are suing to reverse a nearly 30 percent cut in Medicare drug payment rates for certain 340B hospitals that took effect Jan. 1. In advance of the court hearing date, the U.S. Court of Appeals for the District of Columbia Circuit has asked the U.S. Department … [Read more...]
In Court Papers, 340B Hospitals Tell How Massive CMS Cuts Are Causing Irreparable Injury
March 1, 2018— Steep federal drug reimbursement cuts to hospitals in the 340B drug discount program are causing “irreparable injury…by jeopardizing essential programs and services provided to their communities and the vulnerable, poor and other underserved populations, such as oncology, dialysis, and immediate stroke treatment services,” three national hospital groups and three … [Read more...]
Rising Drug Prices Expected to Drive Healthcare Spending in Coming Decade
Feb. 15, 2018 – Rising drug prices will be a major driver of higher U.S. healthcare spending in the coming decade, new healthcare sending projections from the Centers for Medicare & Medicaid Services show. According to CMS’s annual projection, healthcare spending will grow an average of 5.5 percent a year from 2017 through 2026, led by prescription drug spending growth … [Read more...]
Is Trump Budget DOA? What About 340B Changes?
Feb. 13, 2018—Washington, D.C., has many traditions. Cherry blossoms in Spring. Oppressive heat and humidity in Summer. School closings due to snow flurries in Winter. This week marked the latest installment of another: the release of the President’s budget blueprint for the coming year. On Monday, President Trump released what the White House has dubbed “An American Budget” … [Read more...]
Does 340B Really Drive Up the Cost Of Cancer Care?
Feb. 8, 2018— Academic experts continue to question claims that the 340B drug discount program is the cause of consolidations of private physician practices and community-based hospitals. They argue the trend toward consolidation is much more complex and due to a series of factors, including changes in reimbursement policies. In the Feb. 8 issue of Forbes magazine, Duke … [Read more...]
Health Policy Experts Question Findings in Controversial NEJM Study
February 2, 2018—A team of independent health policy experts have questioned the major findings in a recent New England Journal of Medicine (NEJM) study critical of the 340B drug pricing program. In its Jan. 24 issue, the journal published a study authored by Sunita Desai, Ph.D., and J. Michael McWilliams, M.D., Ph.D., that raised questions about whether 340B hospitals are … [Read more...]
Appeals Court Expedites Lawsuit to Stop Deep Medicare Cuts to 340B Hospitals
January 31, 2018—A federal appeals court has agreed to fast-track its consideration of a lawsuit aimed at stopping a nearly 30 percent cut in 340B disproportionate share hospitals’ (DSH) and rural referral centers’ (RRC) Medicare Part B drug reimbursement that took effect on Jan. 1. … [Read more...]